Literature DB >> 33090234

Acute Acquired Concomitant Esotropia From Excessive Application of Near Vision During the COVID-19 Lockdown.

Aldo Vagge, Giuseppe Giannaccare, Fabio Scarinci, Andrea Cacciamani, Marco Pellegrini, Federico Bernabei, Vincenzo Scorcia, Carlo E Traverso, Donatella Bruzzichessi.   

Abstract

The public health measures imposed in many countries to slow the spread of the novel coronavirus (COVID-19) outbreak could have negative effects on children's physical and mental health. The authors describe four cases of acquired concomitant acute esotropia likely caused from excessive application of near vision during the COVID-19 lockdown. [J Pediatr Ophthalmol Strabismus. 2020;57:e88-e91.].
© 2020 Vagge, Giannaccare, Scarinci, et al.

Entities:  

Mesh:

Year:  2020        PMID: 33090234     DOI: 10.3928/01913913-20200828-01

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  4 in total

Review 1.  Online Learning-Related Visual Function Impairment During and After the COVID-19 Pandemic.

Authors:  Qian Fan; Hongxia Wang; Wenjun Kong; Wei Zhang; Zhouyue Li; Yan Wang
Journal:  Front Public Health       Date:  2021-11-29

2.  The effects of topical cycloplegics in acute acquired comitant esotropia induced by excessive digital device usage.

Authors:  Rijo Hayashi; Shimmin Hayashi; Shigeki Machida
Journal:  BMC Ophthalmol       Date:  2022-09-10       Impact factor: 2.086

3.  Effects of remote learning during the COVID-19 lockdown on children's visual health: a systematic review.

Authors:  María Camila Cortés-Albornoz; Sofía Ramírez-Guerrero; William Rojas-Carabali; Alejandra de-la-Torre; Claudia Talero-Gutiérrez
Journal:  BMJ Open       Date:  2022-08-03       Impact factor: 3.006

4.  Acute acquired comitant esotropia precipitated by excessive near work during the COVID-19-induced home confinement.

Authors:  R Neena; S Remya; Giridhar Anantharaman
Journal:  Indian J Ophthalmol       Date:  2022-04       Impact factor: 2.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.